title: [Clinical application of alpha1 adrenoceptor antagonist Naftopidil to the treatment of chronic non-bacterial prostatitis].
abstract: OBJECTIVE
  To study the efficacy and safety of alpha1 adrenoceptor antagonist Naftopidil in the treatment of chronic non-bacterial prostatitis.
  
  
  METHODS
  An opened, self-controlled, multicentral clinical trial was conducted. One hundred and six cases of patients who had been diagnosed as chronic non-bacterial prostatitis (NBP) were treated with Naftopidil (25 mg once a day) for 4 weeks. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and the WBC in the examination of prostatic secretion (EPS) after the treatment.
  
  
  RESULTS
  After 4 weeks therapy, 105 cases were evaluable. After treatment, NIH-CPSI total score were averagely decreased 12.0 points (P <0.001), symptom score 7.9 points (P <0.001) and QOL score 4.1 points (P <0.001). There was a statistically significant difference in WBC count ([(15.2 +/- 15.1)/HP vs (9.5 +/- 12.0)/HP, P < 0.01] and max flow rate(MFR) [(19.2 +/- 4.8) ml/s vs (22.7 +/- 4.9) ml/s, P < 0.01]. The total effective rate were 84.8% in the whole group. The clinical adverse rate was 3.81%, including 3 cases of mild dizziness and 1 case of mild inappetence.
  
  
  CONCLUSIONS
  alpha1 adrenoceptor antagonist Naftopidil is effective and safe for the treatment of chronic non-bacterial prostatitis.
authors.affiliation: Institute of Urology, Peking University, Department of Urology, Peking University First Hospital, Beijing, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.forename: Ning-chen
authors.initials: NC
authors.lastname: Li
authors.forename: Qiang
authors.initials: Q
authors.lastname: Ding
authors.forename: Song-liang
authors.initials: SL
authors.lastname: Cai
authors.forename: Hong-xu
authors.initials: HX
authors.lastname: Huo
authors.forename: Shao-yan
authors.initials: SY
authors.lastname: Chen
authors.forename: Xiao-jian
authors.initials: XJ
authors.lastname: Gu
authors.forename: Shi-ping
authors.initials: SP
authors.lastname: Chen
authors.forename: Yan-qun
authors.initials: YQ
authors.lastname: Na
mesh_terms: D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D002908:Chronic Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011472:Prostatitis / Q000188:drug therapy*
chemical_list: D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; C064357:naftopidil